OPKO Health, Inc. (NASDAQ:OPK) Expected to Post Quarterly Sales of $317.40 Million

Equities research analysts expect that OPKO Health, Inc. (NASDAQ:OPKGet Rating) will announce sales of $317.40 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for OPKO Health’s earnings. The lowest sales estimate is $302.50 million and the highest is $327.10 million. OPKO Health posted sales of $442.40 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 28.3%. The company is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that OPKO Health will report full-year sales of $1.10 billion for the current year, with estimates ranging from $1.09 billion to $1.12 billion. For the next financial year, analysts expect that the firm will report sales of $1.07 billion, with estimates ranging from $945.10 million to $1.20 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for OPKO Health.

OPKO Health (NASDAQ:OPKGet Rating) last issued its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). OPKO Health had a negative net margin of 7.49% and a negative return on equity of 6.86%. The company had revenue of $329.20 million during the quarter, compared to the consensus estimate of $331.45 million. During the same quarter last year, the firm posted $0.05 earnings per share. The company’s quarterly revenue was down 39.6% on a year-over-year basis.

Several equities analysts recently weighed in on the stock. Barrington Research cut shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Monday, January 24th. StockNews.com assumed coverage on shares of OPKO Health in a report on Thursday, March 31st. They set a “sell” rating for the company. TheStreet downgraded shares of OPKO Health from a “c” rating to a “d+” rating in a research note on Friday, February 25th. Zacks Investment Research cut shares of OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research report on Monday, January 24th. Finally, Piper Sandler dropped their target price on shares of OPKO Health from $6.00 to $5.00 in a research note on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.00.

In other OPKO Health news, Vice Chairman Elias A. Zerhouni bought 89,600 shares of OPKO Health stock in a transaction on Tuesday, May 10th. The stock was bought at an average price of $2.79 per share, with a total value of $249,984.00. Following the completion of the acquisition, the insider now owns 89,600 shares in the company, valued at $249,984. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Phillip Md Et Al Frost purchased 35,000 shares of the business’s stock in a transaction dated Monday, March 14th. The shares were purchased at an average cost of $3.04 per share, with a total value of $106,400.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 1,874,600 shares of company stock valued at $5,600,884. Company insiders own 41.47% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Cornerstone Advisory LLC acquired a new stake in shares of OPKO Health during the 4th quarter valued at approximately $29,000. Humankind Investments LLC bought a new position in shares of OPKO Health in the first quarter worth $37,000. Guggenheim Capital LLC bought a new position in shares of OPKO Health in the first quarter worth $38,000. Point72 Hong Kong Ltd bought a new position in shares of OPKO Health in the first quarter worth $39,000. Finally, Beacon Pointe Advisors LLC bought a new position in shares of OPKO Health in the first quarter worth $49,000. 27.83% of the stock is owned by hedge funds and other institutional investors.

Shares of OPKO Health stock opened at $2.99 on Friday. The company has a current ratio of 2.44, a quick ratio of 2.12 and a debt-to-equity ratio of 0.13. The business has a 50-day moving average price of $3.20 and a two-hundred day moving average price of $3.64. OPKO Health has a 1-year low of $2.43 and a 1-year high of $5.25. The company has a market cap of $2.04 billion, a P/E ratio of -16.61 and a beta of 1.88.

OPKO Health Company Profile (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Featured Articles

Get a free copy of the Zacks research report on OPKO Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.